Author Archive: AZBio

Final Steel Beam Tops Off The Refinery Building at the UA Tech Park at The Bridges 

Posted on by

 

TUCSON, Ariz.–  The steel frame and concrete floors are coming to completion at The Refinery. The final beam of The Refinery was placed, topping off the steel framework for the 120,000 square foot structure.  The Refinery is the kickoff building to the new UA Tech Park at The Bridges, an extension campus birthed from the success of the UA Tech Park near Interstate 10 and Rita Road.  Continue reading→

Are COVID-19 Vaccines Safe and Effective?

Posted on by

COVID-19 Vaccines are viewed as the light at the end of the tunnel.  We are not there yet but we will get there.  Hundreds of millions of people in the United States and billions of people globally will need to be immunized against COVID-19.  But, are these vaccines safe and effective?  Would you recommend that someone you love get one?

Continue reading→

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

Posted on by

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.Continue reading→

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Posted on by
  • Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
  • 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28
  • Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa
  • Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting

[1] The B.1.351 lineage also known as 501Y.V2 variant and 20H/501Y.V2 (formerly 20C/501Y.V2) is a variant of SARS-CoV-2, the virus that causes COVID-19Continue reading→

Equality Health and General Atlantic Announce Strategic Partnership to Help Drive Continued Expansion of Equality’s Value-Based Primary Care Network and Technology Solutions

Posted on by

Strategic investment from General Atlantic to help enable Equality Health in furthering its mission of increasing access to care, lowering costs and improving outcomes for underserved individuals, families and communities

Equality Health to acquire actuarial firm, Daraja Services, to deepen healthcare economics capabilitiesContinue reading→